Swisscom-backed biopharmaceutical company Immatics Biotechnologies closed its series D round yesterday at €34m ($46m) after raising a second tranche worth €22m ($29.8m).
Germany-based Immatics secured the funds from existing investors including venture capital firms Dievini Hopp Biotech and Wellington Partners, and AT Impf, the family office of Andreas and Thomas Struengmann.
All three investors participated in Immatics’ $75m series C round in 2010 along with Mona Lisa Fund, the venture firm in which telecommunications company Swisscom is the sole limited partner.
Immatics develops immunotherapies to combat cancer, and will use the latest funding to support a Phase 3 trial it is conducting for its lead cancer vaccine, IMA901.
The company has now raised approximately €142m ($192m) since it was founded in 2000. Existing investors also include 3i, KfW, National Technology Enterprises Company, EMBL Technology Fund, Grazia Equity and Merifin Capital.